Tagrisso (osimertinib) — Medica
Non-Small Cell Lung Cancer – Post Tumor Resection, Adjuvant Therapy
Initial criteria
- age ≥ 18 years
- Patient has completely resected disease
- Patient has EGFR exon 19 deletion or exon 21 (L858R) substitution mutation as detected by an approved test
- Patient had received previous adjuvant chemotherapy OR is ineligible to receive platinum-based chemotherapy
Approval duration
3 years